Retrophin (RTRX) Tops Q4 EPS by 29c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Retrophin Reports Fourth Quarter and Full Year 2015 Financial Results
February 25, 2016 4:01 PM ESTFull year 2016 revenues projected to be $130.0 to $140.0 million
Top-line data from sparsentan Phase 2 DUET study expected 3Q16
Clinical trial evaluating efficacy of RE-024 in PKAN to initiate in 2016
SAN DIEGO, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today reported its fourth quarter and full year 2015 financial results.
Net product sales for the fourth quarter 2015 were $30.4 million, compared to net product sales of $14.1 million for the same period in 2014Net product sales for the full... More